Recall Register

Drug recall: ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx only, STAQ Pharma…

Class II FDA enforcement event 93505. Recall start date: . Status in the FDA record: Completed.

Reason for recall, in the words of FDA

STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigation, they determine the source of the issue was with the bag manufacturer who released bags Lot # 134142-001A which had failed internal QC tests for leaks.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

STAQ Pharma, Inc. started this drug recall on 29 Nov 2023. The firm address in the FDA record is in Denver, CO. FDA put the recall in Class II. FDA event 93505 has 1 product record. The first FDA enforcement report date is 13 Dec 2023. The record gives the status Completed.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide within the United States

Recalling firm

STAQ Pharma, Inc., Denver, CO.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 93505: product records
Recall numberProductQuantityClassStatusReport date
D-0147-2024ROPivacaine HCl 0.2% PF in Sodium Chloride 1,000 mg/500 mL (2 mg per mL) Injection, 500 mL bags, Rx only, STAQ Pharma Inc. 14135 E 42nd Ave, Unit 50, Denver, Colorado 80239, NDC 73177-0109-26,2616 bagsClass IICompleted13 Dec 2023

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2023
281
Share of these events in Class II
59%
Product records in this event
1Median of the firm: 2
Events of the firm on the register
3

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 93505. https://recallregister.com/fda/ii/93505/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide within the United States
What quantity of product is in FDA event 93505?
The FDA record gives this quantity: 2616 bags
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2023 have the same class?
59% of the 281 drug events that started in 2023 are in Class II.